We continue to be active in research and routinely present our research annually at National and International meetings. In addition, we publish our research regularly in multiple peer reviewed journals.
Title: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA)
Brief Description: Comparing Albuterol v. Albuterol + Budesonide
Sponsor: AstraZeneca
PI: Sankaran Krishnan
https://clinicaltrials.gov/study/NCT06307665?term=acadia&rank=1
Title: A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)
Brief Description: New Oral Agent for Asthma
Sponsor: Areteia Therapeutics
PI: Sankaran Krishnan
https://clinicaltrials.gov/study/NCT05763121?term=exhale-2&rank=1
Title: Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/ Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Brief Description: Biologic for 2-5 Year Olds
Sponsor: Sanofi
PI: Sankaran Krishnan
https://clinicaltrials.gov/study/NCT06191315?term=trekids&rank=1
Title: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/ Long-acting Beta-agonist (ICS/ LABA) in Comparison to ICS Dose Escalation to High Dose ICS/ LABA in Adolescent and Adult Patients With Uncontrolled Asthma (AIM4:Next Step)
Brief Description: Biologic Added to Medium Dose Controller Medication v. High Dose Controller Medication Alone
Sponsor: Regeneron
PI: Sankaran Krishnan
https://clinicaltrials.gov/study/NCT06572228?term=R668-AS-2373&rank=1
Title: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/ Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Brief Description: Albuterol v. Albuterol + Fluticasone
Sponsor: Teva Pharmaceuticals
PI: Allen Dozor
https://clinicaltrials.gov/study/NCT06052267?term=FpA-AS-30094&rank=1
Title: A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
Brief Description: New mRNA Therapy for CF
Sponsor: ReCode Therapeutics
PI: Allen Dozor
https://clinicaltrials.gov/study/NCT06237335?term=rct2100&rank=1
Title: A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
Brief Description: New inhaled CFTR (HSV-1)-derived vector for CF
Sponsor: Krystal Biotech
PI: John Welter
https://clinicaltrials.gov/study/NCT05504837?aggFilters=status:rec&term=krystal%20biotech&cond=cystic%20fibrosis&rank=1
Title: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG)
Brief Description: 1 IV Antibiotic v. 2 IV Antibiotics for treatment of Pulmonary Exacerbation with Pseudomonas
Sponsor: Cystic Fibrosis Foundation
PI: Allen Dozor
https://clinicaltrials.gov/study/NCT05548283?term=stop-360&rank=1
Title: Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
Brief Description: Observational Study For People With CF
Sponsor: Cystic Fibrosis Foundation
PI: Allen Dozor
https://clinicaltrials.gov/study/NCT05639556?term=strong-cf&rank=1
Title: A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Brief Description: Observational Study For People With CF Not Taking Modulators
Sponsor: Cystic Fibrosis Foundation
PI: John Welter
https://clinicaltrials.gov/study/NCT06504589?term=REACH-OB-23&rank=1
Title: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis
Brief Description: New IV Drug for People With CF with Pseudomonas
Sponsor: Clarametyx Biosciences
PI: John Welter
https://clinicaltrials.gov/study/NCT06159725?term=CMTX101&rank=2
Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection
Brief Description: Nebulized phage for adults with CF with chronic pseudomonas aeruginosa
Sponsor: BiomX
PI: John Welter
https://clinicaltrials.gov/study/NCT06998043?term=biomx&rank=1#more-information
Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation
Brief Description: New Add-On Therapy for People with CF Taking Trikafta®
Sponsor: Sionna Therapeutics Inc.
PI: John Welter
https://clinicaltrials.gov/study/NCT07108153?term=NCT07108153&limit=10&sort=@relevance&rank=1
Title: A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY® Study)
Brief Description: New Medicine for both CF and Non-CF Bronchiectasis
Sponsor: Boehringer Ingelheim
PI: John Welter
https://clinicaltrials.gov/study/NCT06872892?term=1397-0014&limit=10&sort=@relevance&rank=1
Title: Study of Oral Upadacitinib and Subcutaneous/ Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (SELECT-sJIA)
Brief Description: Comparing Two Biologics for Systemic Juvenile Idiopathic Arthritis
Sponsor: AbbVie
PI: Christine Hom
https://clinicaltrials.gov/study/NCT05609630?term=m14682&rank=1
Title: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab (KnaPsAck)
Brief Description: Comparing Two Biologics for Juvenile Psoriatic Arthritis
Sponsor: AbbVie
PI: Christine Hom
https://clinicaltrials.gov/study/NCT06100744?term=m23732&rank=1
Title: A Phase III, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus (SLE) While on Background Standard of Care Therapy
Brief Description: IV Drug for Pediatric Systemic Lupus Erythematosus (SLE)
Sponsor: AstraZeneca
PI: Christine Hom
https://clinicaltrials.gov/study/NCT05835310?term=D3461C00030&limit=10&sort=@relevance&rank=1
Title: A Phase 2 Basket Study of Vosoritide in Children With Turner Syndrome, SHOX Deficiency and Noonan Syndrome With an Inadequate Response to Human Growth Hormone
Brief Description: Comparing Two Types of Growth Hormone for Children with Turner, SHOX, or Noonan
Sponsor: BioMarin Pharmaceutical
PI: Shilpa Mehta
https://clinicaltrials.gov/study/NCT06668805?term=111-211&rank=2